The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), Johnson & Johnson (Gold), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Fixed-duration dose-reduced ibrutinib plus venetoclax: importance of toxicity reduction in CLL
Paolo Ghia, MD, Vita-Salute San Raffaele University, Milan, Italy, comments on the importance of managing adverse events associated with novel therapies, particularly BTK inhibitors. Dr Ghia highlights that the TAILOR (NCT05963074) study proposes a proactive approach to mitigating cardiovascular events in patients with chronic lymphocytic leukemia (CLL) receiving dose-reduced fixed-duration ibrutinib plus venetoclax in the frontline setting. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, in fact, we know that the new, the novel therapies biologics are very effective but they also carry some adverse events and therefore we have to be aware of that and we learn that in particular when these molecules, in particular the BTK inhibitors, have been used as a continuous therapy and therefore of course these adverse events may occur every moment during the 10 years where we could treat the patients...
Yeah, in fact, we know that the new, the novel therapies biologics are very effective but they also carry some adverse events and therefore we have to be aware of that and we learn that in particular when these molecules, in particular the BTK inhibitors, have been used as a continuous therapy and therefore of course these adverse events may occur every moment during the 10 years where we could treat the patients. So now, with the fixed-duration treatment, these issues can still occur, of course, in a less frequent manner, but still, it’s important to know how to manage it. And the TAILOR study is really proposing the way of being proactive in dose reducing the ibrutinib BTK inhibitor, for the simple reason that in that way we think we can prevent or we can limit the frequency of cardiovascular events in particular in patients who are assuming the combination of ibrutinib plus venetoclax in the frontline setting.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
